The development of a drug able to distinguish between tumor and host cells has been long
sought, but the solid tumor microenvironment (TME) confounds many current therapeutics …

Pancreatic ductal adenocarcinoma is an aggressive disease with an extremely low survival
rate. This is due to the (i) poor prognosis and (ii) high resistance of the disease to current …

Chemoresistance is a serious concern for treating cancer patients. It is especially important
in the aggressively advancing malignancies such as pancreatic cancer. Patients can acquire …

Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic cancer with limited
treatment options. There is an urgent need for tools that monitor therapeutic responses in …

Abstract Poly (acrylic acid)(PAA) is a weak polyelectrolyte presenting negative charge at
basic condition when the carboxylic group loses a proton. These carboxylate group can …

Aquesta tesi s' ha realitzat al Laboratori de Modelització de Teràpies Anti-tumorals en Ratolí
dirigit per la Dra. Laura Soucek al Programa de Recerca Preclínica del Vall d'Hebron Institut …

Pancreatic cancer is one of the deadliest cancer types, and current therapeutic strategies
are often unsatisfactory. Therefore, novel approaches are necessary to fight against this …

Pancreatic cancer or pancreatic ductal adenocarcinoma (PDAC), is the deadliest type of
cancerous malignancy with a survival rate of only 3.7% after 5 years. The first line current …

Despite major advancements in cancer treatment, survival rates for patients with pancreatic
cancer have shown minimal improvement over the last forty years [1]. Pancreatic ductal …

While much progress has been made in the war on cancer, shortcomings in the drug
development process have kept anti-cancer clinical trial success rates low. One of the many …